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Edited by Paul BertoneAbstract Deregulations of EGFR endocytosis in EGFR-ERK
signaling are known to cause cancers and developmental disor-
ders. Mutations that impaired c-Cbl–EGFR association delay
EGFR endocytosis and produce higher mitogenic signals in lung
cancer. ROCK, an eﬀector of small GTPase RhoA was shown to
negatively regulate EGFR endocytosis via endophilin A1. A
mathematical model was developed to study how RhoA and
ROCK regulate EGFR endocytosis. Our study suggested that
over-expressing RhoA as well as ROCK prolonged ERK activa-
tion partly by reducing EGFR endocytosis. Overall, our study
hypothesized an alternative role of RhoA in tumorigenesis in
addition to its regulation of cytoskeleton and cell motility.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Enhanced EGFR-ERK signaling is related to various cellu-
lar processes [1], cancers [2], and developmental disorders [3].
Apart from over-expression and gain of function mutations
[4,5], enhanced signaling can be facilitated by increased EGFR
stability via reduction of its internalization and subsequent
degradation [6–12]. The dynamics of EGFR endocytosis sig-
niﬁcantly aﬀects the magnitude and timing of EGFR-ERK sig-
naling. For instance, EGFR endocytosis has been found to
partly contribute to the transient activation of ERK signal in
PC12 cells [13]. The dynamics of ERK activation has profound
functional implications in aﬀecting cell fate (proliferation or
diﬀerentiation) [14,15] and in promoting tumorigenesis [16],
cardiovascular disease [17,18], and urinary bladder dysfunc-*Corresponding author. Address: Bioinformatics and Drug Design
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doi:10.1016/j.febslet.2008.05.026tion [19]. Therefore, understanding how the dynamics of
EGFR endocytosis aﬀects EGFR-ERK signaling is an impor-
tant issue to address.
Wild-type EGFR undergoes rapid endocytosis from the
plasma membrane followed by lysosomal degradation. How-
ever, Shtiegman et al showed that mutations such as L858R
and L858R/T790M at EGFR that impaired c-Cbl–EGFR
association undergo signiﬁcantly slow endocytosis than wild
type EGFR. Thus, these EGFR mutants resist ligand-induced
degradation and their phosphorylated forms are detectable
even several hours after stimulation with EGF [8]. As a result,
the relatively slow clearance of mutant EGFR molecules en-
ables persistent signaling leading to stronger mitogenic and
antiapoptotic signals that may leads to cancers.
In addition to speciﬁc mutations on EGFR that impaired c-
Cbl–EGFR association, there is alternative mechanism that
causes delayed EGFR endocytosis. The small GTPase RhoA
has been identiﬁed as a negative regulator of EGFR endocyto-
sis via its eﬀector Rho kinase (ROCK) to endophilin A1-med-
iated crosstalk in speciﬁc cell types [12]. Activated EGFR
recruits Grb2 to mediate EGFR binding to c-Cbl, which sub-
sequently initiate EGFR internalization and degradation pro-
cess [20]. An important step is the binding of adaptor proteins
CIN85 and Eps-15 to the EGFR and c-Cbl complex, which
subsequently recruits endophilin, dynamin-2 as well as clathrin
interacting proteins such as BAD2 and AP2 to drive clathrin
assembly and budding that leads to EGFR endocytosis. How-
ever, activation of the RhoA eﬀector ROCK phosphorylates
endophilin A1 at Thr-14 that hinders the recruitment of endo-
philin A1 to the EGFR–c-Cbl–CIN85 complex, thereby reduc-
ing the level of EGFR endocytosis [12].
Apart from its regulatory role in EGFR endocytosis, RhoA
as a small GTPase like Ras, acts as a molecular switch cycling
between inactive GDP-bound and active GTP-bound forms
and play important roles in regulating cytoskeleton formation
and cell migration [21] as well as ERK activation via other
mechanisms [22]. For instance, RhoA is required for the sus-
tained ERK signal by repressing the Rac/Cdc42 pathway
allowing expression of cyclin D1 in mid-G1 phase of NIH-
3T3 cells [22]. These eﬀects are expected to collectively contrib-
ute to the observed facilitating actions of active RhoA onblished by Elsevier B.V. All rights reserved.
Fig. 1. Pathway model used in this study.
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roles of RhoA in enhanced EGFR-ERK signaling [12] and
the observations that it is over-expressed in several cancer cell
lines possibly involved in cancer cell invasion and metastasis
[24,25], it is important to study the eﬀects of RhoA on the
dynamics of EGFR endocytosis in regulating EGFR-ERK sig-
naling via endophilin A1-mediated RhoA-EGFR crosstalk.
Simulation models of EGFR-ERK pathway have been
extensively developed and analyzed by several groups to study
important biological events associated with ERK activation
such as proliferation and diﬀerentiation [26–29]. Kholodenko
et al. have used ODE-based approach to develop a EGFR sig-
naling network model to investigate the short-term pattern of
cellular responses to EGF in rat hepatocytes [29]. This model
consists of 25 reactions involving 23 diﬀerent reacting species
that include crosstalk to phospholipase C gamma (PLCc).
The kinetic parameters in this model are based on the scientiﬁc
literature or derived from basic physicochemical quantities.
Similarly, Brightman and Fell have developed an ODE-based
mathematical model of the EGF signal-transduction pathway
in PC12 cells to investigate the factors inﬂuencing the kinetics
of ERK cascade activation [28]. There are 30 reactions involv-
ing 29 reacting species containing modules of the activation
and internalization of EGFR. From these established mathe-
matical models of EGFR-ERK pathway, Schoeberl et al.
[27] have developed a more detailed ODE-based mathematical
model (125 reactions involving 94 reacting species) describing
the dynamics of the EGFR-ERK signal-transduction pathway
to investigate the eﬀects of receptor internalization on the
ERK cascade [27]. They investigated the signal to response
relationship between the binding of EGF to its receptor at
the cell surface as well as the activation of downstream pro-
teins in the signaling cascade.
To the authors knowledge, mathematical model of endophi-
lin-mediated EGFR endocytosis regulated by RhoA and its
eﬀector ROCK has not been developed. Given that deregula-tion of endophilin-mediated EGFR endocytosis can result in
excessive ERK signaling and cancers, it is important to
develop a mathematical model to understand its regulation
at systems level. In this work, by extending the published
ODE-based mathematical models of EGFR-ERK pathway
[27–32], we developed a generic EGFR-ERK pathway simula-
tion model that include endophilin A1-mediated RhoA-EGFR
crosstalk (Fig. 1) to speciﬁcally study the relevant eﬀects in
those cell types that contain this crosstalk. As shown in Fig.
1 we also included scaﬀold protein MEKK1 that cross-talks
RhoA to Raf-MEK-ERK cascade to capture the overall eﬀects
of RhoA on ERK activation. Detailed molecular interactions
and the corresponding kinetics data were obtained from those
used in the published simulation models and further search of
literatures. Our simulation model was validated by evaluating
whether the simulated results are in agreement with published
experimental and computational ﬁndings. The validated model
was then used to study the possible eﬀects of the over-expres-
sion of RhoA and its eﬀector ROCK on the duration and de-
gree of ERK activation as malfunction of RhoA and ROCK
had been observed in several types of cancers such as breast
and colon cancers [33,34].2. Results and discussion
2.1. Model validation against observed eﬀects of impaired c-Cbl–
EGFR association by EGFR mutations on EGFR
endocytosis and signaling in lung cancer.
High levels of EGFR leads to prolonged ERK signal that is
known to be associated with cancers. Recent study by Shtieg-
man et al. showed that EGFR association with c-Cbl is im-
paired by speciﬁc mutations in EGFR such as L858R/
T790M. These mutations hindered EGFR ubiquitination and
endocytosis leading to prolonged EGFR signaling in lung can-
cer [8]. These known mutational eﬀects were used to validate
C.Y. Ung et al. / FEBS Letters 582 (2008) 2283–2290 2285our model developed in this study. We ﬁrst examined the eﬀects
of the amount of c-Cbl in relation to internalized EGFR. We
found that at normal state of c-Cbl–EGFR binding, increasing
the amount of c-Cbl promotes EGFR endocytosis as showed in
increased amount of internalized endophilin A1-associated
EGFR (Fig. 2a). Higher amount of internalized EGFR subse-
quently reduced the duration of ERK activation (Fig. 2b).
Hence, the trends of our simulation results are consistent with
the observation made by Shtiegman et al. that c-Cbl attenuated
ERK signals via enhanced receptor endocytosis [8].
We next examine the eﬀects of impaired c-Cbl–EGFR bind-
ing in our model. To mimic the eﬀects of speciﬁc EGFR muta-
tions that impair c-Cbl–EGFR association the Kf value of
respective equation was reduced by 100- and 1000-folds (Eq.
(114) in the Supplementary Table S1). The simulation results
in Fig. 2c showed that reducing the binding strength between
c-Cbl and EGFR by 100- and 1000-folds (0.005 and
0.0005 lM1 s1, respectively) almost diminished endocytosis
of EGFR. As shown in Fig. 2d the reduced amount of internal-Fig. 2. (a) Proﬁle of internalized endophilin A1-associated EGFR concentra
concentration (in units of percentage of initial ERK concentration) at diﬀeren
associated EGFR concentration at diﬀerent phoaphatases Kf value (forward k
active ERK concentration (in units of percentage of initial ERK concentrat
(114) in the Supplementary Table S1).ized receptor caused by this impaired c-Cbl–EGFR association
prolonged ERK activation. This prolonged ERK activation
causes stronger mitogenic signal that eventually leads to
uncontrolled cell proliferation in cancers.
2.2. Model validation against reported experimental and
simulation studies of EGFR-ERK signaling
We also validated our model with other published experi-
mental and simulation studies on EGFR-ERK signaling. The
validated results are shown in Fig. 3a–d in which simulated
trends of time-dependent protein concentration and activity
proﬁles of ERK, PP2A, MKP3, and RhoA are in reasonable
agreement with experimentally determined proﬁles. For in-
stance, at 50 ng/ml of EGF, the simulated ERK activation
peaks at 5 min and decayed within 50 min (Fig. 3a). The sim-
ulated result is consistent with experimental ﬁnding that treat-
ment of 50 ng/ml and 100 ng/ml EGF in PC12 cells transiently
activates ERK which peaks within 5 min and decays within
30–60 min [31].tion at diﬀerent Cbl-CIN85 concentrations. (b) Proﬁle of active ERK
t Cbl-CIN85 concentrations. (c) Proﬁle of internalized endophilin A1-
inetic value for Eq. (114) in the Supplementary Table S1). (d) Proﬁle of
ion) at diﬀerent phoaphatases Kf value (forward kinetic value for Eq.
Fig. 3. (a) Proﬁle of active ERK concentration (in units of percentage of initial ERK concentration) upon activation by EGF. (b) Proﬁle of active
ERK concentration (in units of percentage of initial ERK concentration) at diﬀerent phoaphatases PP2A concentrations. (c) Proﬁle of active ERK
concentration (in units of percentage of initial ERK concentration) at diﬀerent phoaphatases MKP3 concentrations. (d) Proﬁle of active RhoA
(RhoGTP) concentration at diﬀerent RhoA (RhoGDP) concentrations.
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with two additional published simulation results and experi-
mental data. As shown in Fig. 3b, low levels of PP2A (from
0.005 to 0.01 lM) that diﬀer by 2-folds show little eﬀect on
the change of maximal amount of active ERK but substan-
tially aﬀect the duration of ERK activation (Fig. 3b). On the
other hand, low levels of MKP3 (from 0.0005 to 0.001 lM)
show little eﬀect on the change of maximal amount of active
ERK but signiﬁcantly aﬀect the duration of ERK activation,
as the period of ERK activity within these low levels is signif-
icantly extended (Fig. 3c). However, high levels of MKP3
(from 0.005 to 0.01 lM) signiﬁcantly decrease the duration
of ERK activation more than the change of maximal amount
of active ERK. These simulated results are consistent with the
results of a reported simulation study [35]. It is noted that, at
higher levels of PP2A and MKP3, the degree and duration of
active ERK decreases. In addition, for RhoA activation proﬁle
increasing initial concentrations of GDP-bound RhoA in-
creases the level of active GTP-bound RhoA (Fig. 3d). This
showed that at normal cycle of RhoA the activity or amountof active GTP-bound RhoA is directly correlated with the
amount of inactive GDP-bound RhoA.
2.3. Eﬀects of RhoA and ROCK on EGFR endocytosis via
endophilin A1-mediated crosstalk
From the above validated results, we next explored the reg-
ulation of RhoA and ROCK on EGFR endocytosis. Active
GTP-bound RhoA activates its eﬀector ROCK. The activated
ROCK subsequently phosphorylates endophilin A1 at Thr-14
thereby preventing its recruitment to the EGFR-c-Cbl-CIN85
complex leading to delayed endocytosis of EGF-bound EGFR
to the lysosomal pathway [12,36]. As the extent and duration
of ERK activation is dependent on the amount of active
EGFR in cell membrane, increased amount of RhoA or
ROCK is expected to prolong ERK activation. We ﬁrst
showed that amount of internalized endophilin A1-associated
EGFR is dependent on amount of active ROCK. Simulation
results shown in Fig. 4 indicated that increased amount of
ROCK reduces the amount of internalized endophilin A1-
associated EGFR, which is consistent with experimental obser-
Fig. 4. Proﬁle of internalized endophilin A1-associated EGFR con-
centration at diﬀerent ROK concentrations.
Fig. 6. Proﬁle of active ERK concentration (in units of percentage of
initial ERK concentration) at diﬀerent increased ROCK concentra-
tions.
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>3.0 lM, both the amount and duration of internalized endo-
philin A1-associated EGFRs are signiﬁcantly decreased. We
next showed that the increased amount of active ROCK is
dependent on activation of RhoA. As shown above increasing
initial concentrations of GDP-bound RhoA increases the level
of active GTP-bound RhoA (Fig. 3d), simulation results
shown in Fig. 5 indicated that increasing the initial concentra-
tions of GDP-bound RhoA signiﬁcantly enhances the activa-
tion of ROCK. The simulation results suggested that amount
of active ROCK is indeed dependent on amount of active
RhoA that is consistent with experimental facts that ROCK
is the eﬀector of RhoA [37,38]. Consequently, increased
amount of RhoA has a signiﬁcant impact in preventing the
association of endophilin A1 to the EGFR-c-Cbl-CIN85 com-
plex via its eﬀector ROCK.Fig. 5. Proﬁle of active ROCK concentration at diﬀerent RhoA
(RhoGDP) concentrations.2.4. Eﬀects of RhoA and ROCK on ERK activation
We next examined the overall eﬀects of RhoA to the activa-
tion of ERK in our model. As activation of ERK is dependent
on the amount of active EGF-bound EGFR and RhoA nega-
tively regulates EGFR endocytosis via ROCK and activates
kinase activity of scaﬀold MEKK1, as a whole RhoA plays a
positive regulator of ERK activation in cells containing this
RhoA-EGFR crosstalk. Our simulation results showed that,
when the amount of ROCK is increased from 0.68 lM to
15.0 lM the duration of ERK signaling is slightly prolonged
and its maximal level is slightly decreased (Fig. 6). As indicated
previously in Fig. 4, increased amount of ROCK reduced the
amount of internalized endophilin A1-associated EGFR.
Hence, prolonged duration of ERK activation by increased
ROCK is due to reduced EGFR endocytosis. Our next simula-
tion results indicated that over-expressing RhoA also pro-
longed the duration of ERK activation but with decreased
maximal level of active ERK (Fig. 7).
We next examined the contribution of RhoA in ERK activa-
tion via inhibition of endocytosis of endophilin A1-bound
EGFR by ROCK and RhoA-MEKK1 crosstalk. We ‘‘turned
oﬀ’’ the interaction of RhoA to the scaﬀold protein MEKK1
by setting Kf values of corresponding equations to zero (Eqs.
(178)–(181) in the Supplementary Table S1). In this condition,
increasing the amount of RhoA to the activation of ERK is
only due to delayed EGFR endocytosis mediated by ROCK.
However, turning oﬀ the interaction between RhoA and
MEKK1 does not aﬀect the amount of internalized EGFR.
Over-expressing ROCK in this condition produced similar re-
sults as shown in Fig. 6 and slightly prolonged ERK activation
due to reduced amount of internalized EGFR (data not
shown). Although there is no competitive binding between
RhoA and ERK to MEKK1, increasing amount of GDP-
bound RhoA prolonged ERK activation but to a lesser extend
than that shown in Fig. 7 and the maximal levels of active
ERK were reduced to a slightly larger extend than that shown
in Fig. 6 (data not shown). This is due to the reason that over-
expression of RhoA signiﬁcantly activate ROCK to further re-
duce EGFR endocytosis (as shown in Fig. 5) that enhanced
Fig. 7. Proﬁle of active ERK concentration (in units of percentage of
initial ERK concentration) at diﬀerent decreased RhoA (RhoGDP)
concentrations.
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feedback loop to active SOS. Hence, over-expression of RhoA
causes prolonged ERK activation by reducing EGFR endocy-
tosis but with slight reduced level of active ERK due to this
negative feedback.
Next we ‘‘turned oﬀ’’ the interaction of RhoA to ROCK by
setting Kf values of corresponding equations to zero (Eqs.
(106) and (107) in the Supplementary Table S1). In this condi-
tion, increasing the amount of RhoA to the activation of ERK
is only due to the crosstalk of RhoA to MEKK1. MEKK1 is a
scaﬀold protein that binds ERK2 cascade components such as
Ras, Raf1, MEK1, and ERK2 [39]. The unique feature of
MEKK1 from other scaﬀold proteins is that it possesses a ki-
nase domain that can further activate ERK2 cascade besides
its scaﬀolding role. Binding of Raf1 to MEKK1 activates its
kinase domain. The activated kinase domain of MEKK1 sub-
sequently phosphorylates and hence activates bound MEK1
[40]. Activated MEK1 subsequently phosphorylates ERK2
once it binds to MEKK1. RhoA is capable to bind to MEKK1
and activates its kinase activity to further activate ERK2 [41].
Hence, our simulation results (data not shown) showed that
over-expressing RhoA alone prolonged duration of active
ERK via activating kinase activity of MEKK1. On the other
hand, reduced maximal amount of active ERK with increased
RhoA is partly due to the competitive binding mode of RhoA
and ERK to the overlapping binding sites on the scaﬀold pro-
tein MEKK1 (see Section 4 for detail description of scaﬀold
modeling). These results suggested that RhoA plays indepen-
dent role in regulating the activity of ERK via ROCK-medi-
ated inhibition of EGFR endocytosis and MEKK1-mediated
activation of ERK.
Our simulation results from current mathematical model
suggested that RhoA prolongs the duration of active ERK
via inhibition of endophilin A1-mediated EGFR endocytosis
by ROCK and MEKK1-mediated ERK activation. Overall,
our current mathematical model hypothesizes alternative role
of RhoA in promoting mitogenic signals in tumorigenesis by
prolonging ERK activation in addition to its regulation of
cytoskeleton and cell motility.3. Concluding remarks
Our simulation model was developed to incorporate the ef-
fects of RhoA in regulating EGFR endocytosis via endophilin
A1. Our simulation results suggested that RhoA and its eﬀec-
tor ROCK are negative regulators of EGFR endocytosis via
the crosstalks. In other words, RhoA positively regulates
ERK activation partly via ROCK to the endophilin A1-medi-
ated crosstalk. Elevation of RhoA substantially prolongs the
duration of ERK activation but with reduced maximal amount
of active ERK. It is noted that the eﬀects of collective regula-
tions by other key regulators such as Ras, SOS, PI3K, and
SHP2 [42,43] via other cascades or cross-talks are not covered
in our mathematical model. Further investigation of this and
other relevant cascades and cross-talks is required [44,45]. A
more comprehensive understanding of the primary and sec-
ondary signal transduction roles of RhoA and other key play-
ers in diﬀerent cell and tissue types [46], the mechanism of their
involvement in the collective promotion of cell proliferation
and invasion in carcinoma cells [47], and the mechanism and
eﬀects of anti-proliferative agents targeting these proteins
and pathways [48] await for future studies.4. Materials and methods
4.1. Model development and collection of kinetics parameters
One of the most commonly used approaches to model biological
pathway systems is that of ordinary diﬀerential equations (ODEs).
In general, a diﬀerential equation can be used to describe the chemical
reaction rate that depends on the change of participating species over
time. The temporal dynamic behavior of molecular species in the bio-
logical signaling pathway network can be captured by a set of coupled
ODEs [49]. The overall pathway internal links and architecture of our
mathematical model is shown in Fig. 1. The information for the topol-
ogy of the crosstalk was collected from various published works [27–
32]. All equations for molecular interactions in this study were derived
based on laws of Mass Action. The kinetic parameters for forming pro-
tein–protein interaction complexes in forward (Kf) and complex disso-
ciation in backward reactions (Kb) were used. For enzymatic and
irreversible reactions, the reaction constant (K) and turn over rates
(Kcats) were used instead of the Michaelis–Menten constants (Km) that
are primarily applicable to steady-state models.
Kinetic parameters used in this study are mostly obtained from pub-
lished experimental data. For those kinetic parameters that are
unavailable from experimental data, similarity-based strategies were
used to derive putative kinetic constants. Ranges of kinetic parameters
are constrained based on the literature data and in vivo measurements
of signaling kinetics [27,29–32,50]. A set of coupled ODEs was used to
describe the reaction network. Our model contains 205 equations and
interactions with 194 distinct molecular species, characterized by 313
kinetic parameters and 38 initial molecular concentrations. These
ODEs were then solved using the Ode45 solver of MatLab [51]. The
systems biology markup language (SBML) of our model is also pro-
vided in the Supplementary Material (the Supporting Information
can be found on the FEBS Letters web site).
4.2. Modeling MEKK1 as scaﬀold for crosstalk of RhoA and ERK
The scaﬀold protein considered in this model is MEKK1. The
MEKK1 is represented as MEKK1abcdef in the chemical equations
where a, b, c, d, e, and f are binding sites for Raf1, MEK1, ERK2,
RhoA, p115 RhoGAP, and Ras, respectively [39,41,52–55]. Site ‘‘a’’
corresponds to residues 221-370 which is a proline-rich region, site
‘‘c’’ corresponds to residues 370–559 which constitute PHD domain,
site ‘‘d’’ corresponds to residues 437–456 which constitute PHD
domain, and site ‘‘e’’ corresponds to residues 565–636. Sites ‘‘b’’
and ‘‘f’’ are binding sites of MEK1 and Ras that are correspond-
ing to N-terminal and C-terminal of MEKK1, respectively. For
instance, binding of MEK1 and Ras to MEKK1 can be simpli-
ﬁed as: MEK1 +MEKK1abcdef = MEKK1abMEK1cdef and Ras-
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site ‘‘d’’ is within site ‘‘c’’ that are correspond to the binding of RhoA
and ERK2, we model the binding of these proteins to MEKK1 as com-
petitive manner where only one component binds at one time.
The kinetics parameters for MEKK1-mediated protein–protein
interactions were obtained from yeast scaﬀold analog Ste5 [40] and
were constrained according to experimental observations. Due to mul-
tiple binding sites on the scaﬀold protein by multiple signaling mole-
cules, the possible combinations for scaﬀold-signaling molecule
complexes are enormous. In this study, only scaﬀold complexes that in-
volved in main processes were considered. The full list of scaﬀold-med-
iated reactions and corresponding kinetics parameters are given in the
Supplementary Table S1.
4.3. Model optimization and validation
Mathematical models developed at systems levels are generally un-
able to reproduce exact quantitative values in all systems but are capa-
ble to produce known behavior or trend that agreed well of those
systems under investigating. For instance, mathematical model devel-
oped for a biological pathway from parameters obtained experimen-
tally from one cell type can behave slightly diﬀerent in another cell
types. The diﬀerent of the behavior of the model in these cell types
can be due to the present or absent of a crosstalk (i.e. the topology
and hence the boundary of the mathematical model) and variation in
values of kinetic parameters used. Hence, in this study we developed
a generic model of EGFR-ERK signaling pathway with endophilin-
mediated RhoA-EGFR crosstalk to investigate the role of RhoA in
regulating endophilin-mediated EGFR endocytosis.
The simulated results are represented in curves of concentrations of
a chemical species over time that are validated against available exper-
imental data. If the trend or dynamics of the curves of a particular
reactant or product behave as the experimental data suggest, then
the model is said to be optimized and can be used to analyze and pre-
dict unknown biological phenomena within the boundary of the mod-
el. If the simulation results were not fair in well agreement with known
experimental facts, then the deﬁnition as well as the boundary of the
model has to be revisited to examine possible errors such as incorrect
interaction kinetics or values of kinetics parameters.
Optimized parameters obtained from previous mathematical models
are not necessarily optimized in current study as the boundaries of
these models are diﬀerent. As a biological network is robust and bind-
ing aﬃnity of protein–protein interactions for proteins in similar fam-
ily that mediate similar types of biochemical reactions (such as Ras and
RhoA) diﬀer within 10-fold range hence the values of kinetics param-
eters obtained from previous models are optimized within these ranges.
Likewise, for parameters that are not available from previous models
are obtained from proteins in similar family. For instance, the param-
eters of RhoA activation cycle are obtained from Ras activation cycle
and are further optimized in 10-fold ranges. The cycle of optimization
and validation are repeated in order to obtain simulated results that
agreed well with known experimental trends.Conﬂict of interest statement
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